🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Geoffrey Fell

Dana-Farber Cancer Institute

ORCID: 0000-0001-6436-6691
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile
1.7Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects

Nature Communications(2022)10.1038/s41467-022-28410-9
Top 16%
1.3DataRank
Top 16%39 citations

Geoffrey Fell, Brian M. Alexander, Adam C. Palmer, Peter K. Sorger, Deborah Plana

Papers

Driven by 15 papers — median percentile 68. Top paper: “Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects”.

Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects

Nature Communications(2022)10.1038/s41467-022-28410-9
Top 16%
1.3DataRank
Top 16%39 citations

Geoffrey Fell, Brian M. Alexander, Adam C. Palmer, Peter K. Sorger, Deborah Plana

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML

Blood Advances(2024)10.1182/bloodadvances.2023012120
N/A
1.2DataRank · unranked
46 citations

Haesook T. Kim, H. Moses Murdock, Michela Ansuinelli, Jennifer Brock, Corey Cutler +18 more

Fine tuning of CpG spatial distribution with DNA origami for improved cancer vaccination

Nature Nanotechnology(2024)10.1038/s41565-024-01615-3
N/A
0.768DataRank · unranked
166 citations

Olivia J. Young, Christopher M. Wintersinger, Frances M. Anastassacos, James I. MacDonald, Giorgia Isinelli +18 more

Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas

Science Translational Medicine(2023)10.1126/scitranslmed.adi0069
N/A
0.736DataRank · unranked
22 citations

Christine Dominas, Geoffrey Fell, Joshua D. Bernstock, Sarah E. Blitz, Debora Mazzetti +18 more

Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1022
N/A
0.604DataRank · unranked
55 citations

Laura M. Spring, Geoffrey Fell, Phoebe Ryan, Neelima Vidula, Arielle J. Medford +8 more

TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2771
N/A
0.574DataRank · unranked
45 citations

Bogang Wu, Haley Barnes, Arielle J. Medford, Bryanna L. Norden, Annika Putur +16 more

Clonal Hematopoiesis in Young Women Treated for Breast Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0050
N/A
0.505DataRank · unranked
28 citations

Geoffrey Fell, Tal Sella, Adam S. Sperling, Craig Snow, Shoshana M. Rosenberg +8 more

Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19

Blood(2022)10.1182/blood.2022018052
N/A
0.494DataRank · unranked
26 citations

Geoffrey Fell, Brody H. Foy, Allison K. Scherer, Christopher J. Gibson, Adam S. Sperling +16 more

KMDATA: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials

Database(2021)10.1093/database/baab037
Top 49%
0.369DataRank
Top 49%4 citations

Robert Redd, Alyssa M. Vanderbeek, Rifaquat Rahman, Bill Louv, Jon McDunn +5 more

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2540
N/A
0.345DataRank · unranked
9 citations

Helen Gandler, Isidora Tošić, Geoffrey Fell, Ashlee Fiore, Olga Pozdnyakova +14 more

Association of pretreatment chest CT abnormalities with trastuzumab deruxtecan–associated pneumonitis.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1106
N/A
0DataRank · unranked
0 citations

Zachary Hartley-Blossom, Geoffrey Fell, Phoebe Ryan, Erika Nakajima, Beverly Moy +5 more

Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma

Leukemia(2022)10.1038/s41375-022-01588-z
N/A
0DataRank · unranked
0 citations

Shruti Bhatt, Kenneth Wen, Zuzana Chyra, Geoffrey Fell, Yu‐Tzu Tai +7 more

Peripheral blood CD3+ T‐cell gene expression biomarkers correlate with clinical frailty in patients with haematological malignancies

British Journal of Haematology(2022)10.1111/bjh.18336
N/A
0DataRank · unranked
5 citations

Ashley Rosko, Gregory A. Abel, Clark DuMontier, Kelly J. Higby, Anays Murillo +4 more

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.10.14.682414
N/A
0DataRank · unranked
0 citations

Leah Krotee, Jason Wu, Lindsey Thornton, Geoffrey Fell, Sonja Herter +19 more

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML

Blood Advances(2025)10.1182/bloodadvances.2025018631
N/A
0DataRank · unranked
0 citations

Haesook T. Kim, H. Moses Murdock, Anna Bosch, Kevin M. Panaro, Felicia Lim +20 more